

Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV Assay for Human Papillomavirus Genotyping

C. Estrade, R. Sahli

WHO HPV LabNet Regional Reference Laboratory for Europe, Institute of Microbiology, Centre Hospitalier Universitaire Vaudois (CHUV), and University of Lausanne, Lausanne, Switzerland

The Anyplex II HPV28 (H28; Seegene) is a new semiquantitative real-time multiplex PCR assay for screening and genotyping 28 human papillomaviruses (HPV) in only 2 reaction wells. H28 was compared to the PGMY-CHUV assay (PG) with 309 archival DNA samples from cervical smears collected over 8 years in our laboratory. H28 and PG were fully concordant at the genotypic level on 228 (73.8%) out of 309 samples: 27 HPV negative and 201 HPV positive. The 201 fully concordant positive samples corresponded to single infections ($n = 145$) and to multiple infections (2 genotypes, $n = 38$; 3 to 5 genotypes, $n = 18$). The remaining 81 samples (26.2%) were either partially concordant ($n = 64$, 20.7%) or fully discordant ($n = 17$, 5.5%). While genotype-specific agreement was nearly perfect ($\kappa = 0.877$), HPV51 was significantly less well detected by H28 and the converse was observed for HPV40, -42, -54, and -68. Sequencing of PG amplicons confirmed HPV51 discordants and suggested the involvement of a possibly local HPV51 subtype. Mismatches in the PGMY09 primers to HPV68a explained most of the HPV68 discordants, confirming the specificity of H28 toward HPV68. With PG as a reference, the sensitivity and specificity of H28 were 93.4% and 99.0%, respectively. Considering H28 as a reference, the sensitivity and specificity of PG were 83.8% and 99.6%, respectively. H28 is a very sensitive and specific HPV genotyping assay suitable for research and clinical use as an adjunct to a clinically validated test. H28 semiquantitative readout ought to be evaluated for primary cervical cancer screening.

High-risk human papillomaviruses (HPV) are the causative agents of cervical cancer (1, 2). Molecular detection of high-risk HPV in cervical smears therefore is used as an adjunct to cytology to identify women at risk for cervical cancer (3–5). Assays that have been clinically validated identify high-risk genotypes as a whole (the hybrid capture II [HCII] assay) or distinguish HPV16 or HPV18 from the other high-risk types as a group (HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68) (Abbott Real-Time high-risk HPV and Roche Cobas 4800 HPV tests). The Abbott and Roche tests have been validated against HCII using cervical intraepithelial neoplasia (CIN) grade 2 or higher as endpoints (6–8). They were also found in these studies to be suitable for primary cervical cancer screening according to published guidelines (9).

In contrast to the clinical application of partial genotyping exemplified by the Abbott and Roche assays mentioned above, comprehensive HPV genotyping is essential in epidemiology and for vaccine surveillance (10). Full HPV genotyping is also useful clinically to identify patients with persisting, type-specific high-risk HPV infections which are known to confer a higher risk of cancer progression than incident infections by the same high-risk type (11). Many published HPV genotyping assays rely on endpoint multiplex PCR followed by reverse hybridization against a panel of type-specific probes immobilized on membranes or beads (12–19). They target at least 25 genotypes: the 14 high-risk HPV genotypes, indicated above, as well as low-risk (HPV6, -11, -42, -44, -53, -54, and -70) or potentially high-risk (HPV26, -69, -73, and -82) genotypes. These assays, including ours, are time-consuming and necessitate some degree of expertise (20). Owing to their ease of use and objective readout, real-time PCR assays capable of detecting a higher number of HPV genotypes are desirable. Such coverage by real-time PCR is, however, challenging. Thus, published multiplex real-time PCR assays for HPV genotyping need at least 6 different PCR wells per sample to overcome the limitations

of present chemistries and equipment, which distinguish at best 3 to 5 targets per well (21).

Seegene recently commercialized the real-time PCR Anyplex II HPV28 kit (H28). H28 is aimed at genotyping 28 HPV in only 2 PCR wells per sample. This system therefore has the potential to greatly simplify HPV genotyping. For this reason, we decided to compare H28 with our in-house PGMY-CHUV (PG) assay described in Chapter 5 of the WHO *HPV Laboratory Manual* (10). PG has been found to be highly comparable to the commercially available linear array (LA; Roche) with some advantages in terms of sensitivity and specificity toward HPV56 and HPV52 (20). PG has also been repeatedly proficient in several laboratories within the WHO HPV Laboratory Network at frequencies at least as good as those of LA (22).

We show here that the present version of H28 overall is more sensitive than and as specific as PG. Among the high-risk genotypes, H28 detected significantly fewer cases of HPV51, possibly in a locally prevalent and subtype-dependent manner, and more cases of HPV68. The latter is a known consequence of the inability of the PGMY primers to efficiently target the HPV68a subtype (23). Supplementing PG with an additional set of an HPV68a-specific primer/probe corrected this defect, confirming the specificity of H28 toward HPV68.

Received 1 October 2013 Returned for modification 21 November 2013

Accepted 5 December 2013

Published ahead of print 11 December 2013

Editor: A. J. McAdam

Address correspondence to Roland Sahli, roland.sahli@chuv.ch.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JCM.02749-13

MATERIALS AND METHODS

Samples. (i) Cervical smear DNA. A total of 298 DNA samples from our biobank were selected from all gynecological patients who submitted more than one cervical smear to our laboratory from May 1999 till December 2012 and who tested HPV positive at least once. An additional subset of 14 samples was also randomly selected among HPV-negative women with atypical squamous cells of undetermined significance (ASC-US). These DNA samples had been purified using MagNApure chemistry (Roche, Rotkreuz, Switzerland) as previously described (20).

A single sample was evaluated from each patient to increase genotype/subtype diversity. Out of the 312 samples, 3 were lost during storage, so 309 samples (99%) were left to be compared. These 309 samples represented 162 ASC-US, 80 low-grade squamous intraepithelial lesion (LSIL), 53 normal, and 14 high-grade squamous intraepithelial lesion (HSIL) samples. This mode of selection enriched for positives to ensure sufficient numbers of individual genotypes for statistical analysis.

(ii) WHO quality control panel. The 2011 WHO HPV proficiency panel was provided by EQUALIS AB (Uppsala, Sweden). It consisted of 43 DNA samples and of 3 cell samples. Only the DNA samples were tested with H28. They corresponded to single and to multiple infections containing 5 to 500 viral genome equivalents per reaction (5 μ l DNA per reaction). The genomes represented in this panel were HPV6, -11, -16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68a, and -68b.

(iii) Ethical issues. This study was approved by our local ethics committee.

PGMY-CHUV assay (PG). PCR using the PGM1 primers and reverse blotting hybridization (RBH) were performed as described in Chapter 5 of the WHO *HPV Laboratory Manual* and its validation study with 5 μ l DNA in a single 50- μ l PCR mixture containing 3 mM MgCl₂ (10, 20). This assay allows genotyping of 31 HPV (6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 42, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 66, 68 [ME180, b subtype], 69, 70, 73, 82, 83, and 84).

Version 2 of PG (PGv2) was designed to resolve HPV68-discordant cases. Compared to PG, it uses an additional HPV68a-specific primer (RSMY09-L, 5'-CGTCCTAATGGGAATTGGTC-3') at 80 nM and an HPV68a-specific probe (5'-CTGATTGTAGGTAGCGGTATG-3').

Anyplex II HPV28. H28 was performed as recommended by the manufacturer (Seegene, Seoul, South Korea) with 5 μ l DNA in each of the two 20- μ l reaction mixtures with primer set A or B. H28 uses HPV-specific dual priming oligonucleotides (DPO) for multiplex (real-time) PCR (24). In addition, it uses a primary HPV type-specific probe (pitcher) carrying an artificial 5' extension and a secondary, artificial, fluorescently labeled probe (catcher) specific to each pitcher. For a given HPV, the catcher is activated by the pitcher's 5' extension oligonucleotide upon its release from the bound pitcher by the exonucleolytic activity of the polymerase. The 5' extension is complementary to the 3' end of the matched catcher. Its binding to the catcher primes DNA synthesis by the polymerase and conversion of the single-stranded catcher to a double-stranded form with concomitant release of quenching and emission of fluorescence. The catchers are labeled with a common fluorophore for a given set of 3 genotypes. Each catcher, and hence its corresponding HPV, can be distinguished from the others sharing the same fluorophore by melting curve analysis at 3 specific steps during the real-time PCR. Since the catchers are totally artificial, their melting temperatures can be well defined and attributed to the HPV type that each catcher represents. This design constitutes the TOCE system, which has already been implemented for the detection of respiratory viruses (25). In addition, knowledge of the step at which the melting curve becomes positive allows us to semiquantify the viral load, from low (+; positive after 40 PCR cycles), to intermediate (++; positive within 31 to 39 cycles), to high (+++; positive before 31 cycles). H28 thus distinguishes semiquantitatively 28 HPV genotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, and 82) in only 2 reactions by taking advantage of the 5 dyes that can be resolved on the CFX96 real-time PCR instrument (Bio-Rad; provided together with the H28 kits by BÜHLMANN Laboratories AG, Schönen-

buch, Switzerland). Data recording and interpretation were automated with the Seegene viewer software according to the manufacturer's instructions.

DNA sequencing and phylogenetic analysis. HPV51- and HPV68-discordant cases were assessed by DNA sequencing of PG amplicons and comparison to the nonredundant nucleic acid GenBank database as described in Estrade et al. (20). DNA sequencing was also performed with the HMB01 primer for HPV51 (13).

Phylogenetic analysis of HPV51 PG amplicons was performed with the tree builder tool of Geneious (Geneious version 7.0.5; Biomatters LTD, New Zealand) using an HPV16 PG amplicon (GenBank accession number AF003027) as an outgroup with 1,000 replicates. The noninformative PGM1 primer sequences were removed from the amplicon sequences prior to alignment and tree building.

Data analysis and statistics. Despite selecting the most recent sample from each patient, some had been stored at -20°C for up to 8 years until reanalysis. PG therefore was repeated simultaneously with H28. PG results were then compared with H28 using correspondence queries in Microsoft Access. For statistics, the genotypes were restricted to the 26 shared by both assays: 18 high risk (HPV16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68, -69, -73, and -82) and 8 low risk (HPV6, -11, -40, -42, -44, -53, -54, and -70). Risk attribution of HPV genotypes was according to Estrade et al. (20).

Tables for statistics were generated with Microsoft Access or Excel, and statistics were performed with GraphPad Prism (GraphPad Software, La Jolla, CA). Agreement of HPV typing results between paired cases was evaluated with the Cohen's kappa (κ) statistics and their uneven distribution evaluated with McNemar's test. Agreement was interpreted as poor ($\kappa < 0.200$), weak ($0.200 < \kappa < 0.401$), moderate ($0.400 < \kappa < 0.601$), strong ($0.600 < \kappa < 0.801$), near perfect ($0.800 < \kappa < 1.000$), and perfect ($\kappa = 1.000$). Statistics for unpaired cases were performed with the two-sided Fisher's exact test using 2-by-2 contingency tables. The trend of association between viral load and discordance was evaluated with the chi-square test for trend.

Nucleotide sequence accession numbers. The 10 HPV51 amplicon sequences are referenced in GenBank with the accession numbers KF707617 to KF707626.

RESULTS

Evaluation of H28 with the 2011 quality control panel from WHO. All 43 DNA samples were correctly identified by H28 (not shown; sensitivity and specificity of 100%). H28 therefore was proficient for the genotyping of the 17 HPV types and subtypes represented in this panel, including those at the lowest concentration of 5 to 50 viral genome equivalents per reaction. Two genotype-sample combinations were missed by PG in comparison (HPV18 at 5 copies per reaction, single infection; HPV31 at 50 copies per reaction, multiple infections). PG was not proficient only for HPV68a, which cannot be efficiently detected with the PGM1 primers (23).

Evaluation of H28 with PG. After restricting the analysis to the 26 genotypes shared by H28 and PG, 293 samples out of 309 were concordantly screened by both assays as HPV positive ($n = 266$) or as HPV negative ($n = 27$), and 16 were discordant (agreement = 94.8%; $\kappa = 0.742$, considered strong) (Table 1). A total of 282 samples were recorded positive by either assay. Of them, 201 (71.3%) were fully concordant at the genotypic level, even with multiple infections containing up to 5 genotypes (single infections, $n = 145$ samples; double infections, $n = 38$ samples; 3 to 5 genotypes, $n = 18$ samples), 64 were partially concordant (double infections, $n = 32$ samples; 3 to 8 genotypes, $n = 32$ samples), and 17 were fully discordant. Among the 17 fully discordant samples, 6 H28-negative sam-

TABLE 1 Comparison of H28 and PG for screening HPV-positive and HPV-negative cases^a

PG result	No. of samples by H28 result		Total no. of samples
	NEG	POS	
NEG	27	10	37
POS	6	266	272
Total	33	276	309

^a PG, PGMY-CHUV; H28, Anyplex HPV28; NEG, negative; POS, positive. A test was considered HPV positive if it was positive for at least one of the 26 genotypes shared by both assays (see Materials and Methods). Agreement, 293/309 = 94.8%; $\kappa = 0.742$, considered as a strong agreement; $P = 0.453$ (McNemar).

ples were recorded as single infections by PG (HPV51, $n = 4$ samples; HPV53 and HPV70, $n = 1$ sample each), 10 PG-negative samples were recorded as single infection ($n = 8$ samples; HPV18, -40, -45, -53, -54 twice, -56, -68) or double infections

($n = 2$ samples; HPV16 and -53, HPV42 and -68) by H28, and 1 was fully discordant among the 266 H28/PG-positive samples (HPV82 with PG and HPV59 with H28).

The genotype-specific comparison of H28 with PG is presented in **Table 2**. While the agreement was nearly perfect (total, 98.71%; $\kappa = 0.877$) considering all 26 genotypes, there was a statistically significant higher number of genotype-sample combinations found by H28 that were not found by PG ($n = 76$) than of those found by PG and not by H28 ($n = 28$, $P < 0.0001$). This was contributed mainly by the low-risk viruses (total L, 7 versus 38, $P < 0.0001$, agreement = 98.18%, $\kappa = 0.826$) in comparison with the high-risk viruses (total H, 21 versus 38, $P = 0.0372$, agreement = 98.94%, $\kappa = 0.899$). Consistent with this observation, the proportion of concordant genotype-sample combinations from the high-risk group (280/339) was significantly higher ($P = 0.0065$, by Fisher's exact test) than from the low-risk group (114/159). Individually, the majority of genotypes exhibited agreement values above 99%, except HPV40, -42, -51, -53, -54, -56, -58, -66,

TABLE 2 Genotype-specific comparison of H28 and PG^f

Genotype ^a	Risk ^b	No. of genotype-sample combinations ^c				% agreement	κ	SD	Int. ^d	McNemar value
		-/-	-/+	+/-	+/+					
6	L	297	1	2	9	99.03	0.852	0.084	np	1.000
11	L	302	0	1	6	99.68	0.921	0.078	np	1.000
16	H	260	2	1	46	99.03	0.963	0.021	np	1.000
18	H	288	2	1	18	99.03	0.918	0.047	np	1.000
26	H	308	0	0	1	100.00	1.000	0.000	pe	1.000
31	H	281	0	1	27	99.68	0.980	0.020	np	1.000
33	H	296	0	0	13	100.00	1.000	0.000	pe	1.000
35	H	300	0	3	6	99.03	0.795	0.115	st	0.248
39	H	294	0	1	14	99.68	0.964	0.036	np	1.000
40	L	301	0	7	1	97.73	0.218	0.182	we	0.023 ^e
42	L	267	1	10	31	96.44	0.829	0.050	np	0.016 ^e
44	L	293	0	1	15	99.68	0.966	0.034	np	1.000
45	H	294	2	1	12	99.03	0.884	0.06	np	1.000
51	H	286	10	0	13	96.76	0.706	0.087	st	0.004 ^e
52	H	281	2	0	26	99.35	0.959	0.029	np	0.480
53	L	269	2	6	32	97.41	0.874	0.044	np	0.289
54	L	287	1	10	11	96.44	0.649	0.098	st	0.016 ^e
56	H	285	0	4	20	98.71	0.902	0.048	np	0.134
58	H	284	0	5	20	98.38	0.880	0.053	np	0.074
59	H	298	1	1	9	99.35	0.897	0.072	np	1.000
66	H	288	1	4	16	98.38	0.856	0.063	np	0.371
68	H	281	0	13	15	95.79	0.677	0.083	st	0.001 ^e
69	H	308	0	0	1	100.00	1.000	1.000	pe	1.000
70	L	297	2	1	9	99.03	0.852	0.084	np	1.000
73	H	295	0	3	11	99.03	0.875	0.071	np	0.2482
82	H	296	1	0	12	99.68	0.958	0.042	np	1.000
Total										
High and low risk		7,536	28	76	394	98.71	0.877	0.012	np	<0.0001 ^e
High risk		5,223	21	38	280	98.94	0.899	0.013	np	0.0372 ^e
Low risk		2,313	7	38	114	98.18	0.826	0.025	np	<0.0001 ^e

^a Only the 26 genotypes shared by both assays were considered for analysis.

^b L, low risk; H, high risk.

^c -/-, negative with both assays; -/+, H28 negative and PG positive; +/-, H28 positive and PG negative; +/+: positive with both assays.

^d Interpretation of the kappa values. we, weak; st, strong; np, near perfect; pe, perfect.

^e $P < 0.05$, two-sided McNemar's test.

^f The total number of samples was 309, giving 8,034 genotype-sample combinations. PG, PGMY-CHUV; H28, Anyplex HPV28. Sensitivity of H28 using PG as a reference, 394/422 = 93.4%; specificity of H28 using PG as a reference, 7,536/7,612 = 99.0%; sensitivity of PG using H28 as a reference, 394/470 = 83.8%; specificity of PG using H28 as a reference, 7,536/7,564 = 99.6%.

TABLE 3 Distribution of HPV40, -42, -54, -51, and -68 according to the infection status

Genotype	Risk ^g	No. of cases ^a				<i>P</i> ^b
		Single infection		Multiple infections		
		Disc.	Conc.	Disc.	Conc.	
40	L	1	0	6	1	1
42	L	0	16	11	15	0.0027 ^f
54	L	2	1	9	10	1
51	H	4 ^c	6 ^d	6	7	1
68	H	1	5	12 ^e	10	0.1727

^a The infection status (single versus multiple) was attributed after combining PG and H28 results. Disc., number of discordant cases; Conc., number of concordant cases.

^b Fisher's two-tailed *P* value addressing whether discordance is associated with the infection status.

^c All fully discordant cases (samples R18, R50, R72, and R289) were confirmed as HPV51 by DNA sequencing.

^d All fully concordant cases (samples R11, R60, R155, R216, R253, and R283) were confirmed as HPV51 by DNA sequencing.

^e Of which one fully discordant case (sample R122, HPV42 and HPV68 by H28) was identified as a single HPV68a infection by PGv2 and DNA sequencing.

^f *P* < 0.05.

^g L, low risk; H, high risk.

and -68. Of those, HPV40, -42, -54, and -68 were significantly more frequently detected by H28 (*P* < 0.05), while the converse was true for HPV51 (*P* = 0.004). Using PG as a reference, the sensitivity and specificity of H28 at the genotypic level were 93.4% and 99.0%, respectively.

Discordance analysis was restricted to the significantly affected genotypes and for two variables: the infection status (multiple versus single infections) and the viral load (20). Among the low-risk genotypes, HPV42 was the only one displaying a significant association between discordance and the sample's multiple infection status (Table 3). A trend for discordance was associated with lower viral loads for HPV40, -42, and 54 (Table 4). No trend was noticed for HPV51 and -68.

For HPV51, all discordants exhibited medium (*n* = 6) to high (*n* = 4) viral loads (Table 4). Sequencing analysis of the 4 discordant single infections and of the 6 concordant single infections confirmed this genotype (Table 3). Phylogenetic analysis indicated that 3 of the 4 discordants clustered as a distinct subtype among the 10 HPV51 cases (data not shown).

For HPV68, 8 out of the 13 discordant cases were identified as HPV68a by PGv2 (see Materials and Methods), 3 remained HPV68 negative, and 2 were not assessed with PGv2, as they were positive for HPV68b as determined originally with PG. The HPV68a single infection identified with PGv2 could be confirmed by DNA sequencing (Table 3).

There was no systematic association of two genotypes during the course of this study with either assay, even with high viral loads as judged by the H28 semiquantitative report and by the PG PCR/RBH signal strengths (not shown). This evaluation therefore supports that H28 is more sensitive rather than less specific than PG for HPV40, -42, -54, and -68 and by extension for other genotypes with the exception of HPV51. Using H28 as a reference, the sensitivity and specificity of PG at the genotypic level were 83.8% and 99.6%, respectively (Table 2).

TABLE 4 Distribution of HPV40, -42, -54, -51, and -68 according to viral load

Genotype	Risk ^d	No. of samples by viral load ^a						<i>P</i> ^b
		+		++		+++		
		Disc.	Conc.	Disc.	Conc.	Disc.	Conc.	
40	L	3	0	4	0	0	1	0.0434 ^c
42	L	3	0	7	15	1	16	0.0010 ^c
54	L	9	1	2	9	0	1	0.0009 ^c
51	H	0	2	6	7	4	4	0.3339
68	H	3	3	9	5	1	7	0.1147

^a +, positive within 41 to 50 cycles; ++, positive within 31 to 40 cycles; +++, positive before 31 cycles by H28 for H28-positive cases. Weak or stochastic (+), medium (++) or strong (+++) PCR/RBH signal by PG for H28-negative cases (20). The numbers indicated are pooled from single and multiple infections. Disc., number of discordant cases; Conc., number of concordant cases.

^b Chi-square analysis for trend addressing whether discordance is associated with viral load.

^c *P* < 0.05.

^d L, low risk; H, high risk.

DISCUSSION

Overall, H28 performed very similarly to PG. However, H28 detected more positives, suggesting that it truly is more sensitive than PG. This conclusion is supported by H28 correct identification of all genotypes even at the lowest concentration (5 to 50 viral genome equivalents per reaction) in the 2011 WHO proficiency panel samples and in the 2013 panel (S. A. Nordbø, personal communication). Although it was proficient with both panels, PG was in comparison less sensitive in 3 samples involving HPV18 (5 genome equivalents, 2011 panel), HPV31 (50 genome equivalents, 2011 panel), and HPV56 (50 genome equivalents, 2013 panel).

Higher sensitivity rather than lower specificity of H28 was also supported by its not recording systematic double infections involving the same genotypes during this work. Based on these results, we concluded that the H28-positive/PG-negative results were indeed true positives. It therefore seemed reasonable to also consider H28 as a reference against which to compare PG. Under this condition, the sensitivity of PG was lower, at 83.8% (versus 93.4% for H28 using PG as a reference), and the specificity was slightly higher, at 99.6% (versus 99.0%). Enrichment of samples from patients known to have been positive at least once by PG introduced a selection bias that may have lessened the difference in sensitivity between H28 and PG. This selection bias was minimal, however, considering that more than 67% of the genotype-sample combinations (not shown) were contributed by multiple infections (42%, not shown), which were more likely to be recorded as HPV positives independently of the assay.

The reevaluation of the HPV51 discordants confirmed our results except for one case, which could not be amplified on retesting at Seegene using different PCR assays. This sample (R50) was recorded as weakly positive by PG with stochastic amplification. In contrast, the remaining 3 HPV51 subtypes from discordant single infections clustered phylogenetically and exhibited mismatches affecting the H28 primers/probe (Seegene, personal communication). These HPV51 subtypes were not represented in nucleic acid databases. They therefore were likely to be suboptimally detected by H28, whose sensitivity relies on type-specific primers and probes strictly adapted to published sequences (25). It remains to be determined, however,

whether the H28 false-negative HPV51 subtypes are specific to our study population or distributed worldwide.

The PGMY primers used in PG are degenerate to identify potentially unknown genotypes (13). Broad-range detection benefits from this approach at the cost of sensitivity, especially with low viral loads in multiple infections (20). The trends for discordance with low viral loads and with multiple-infection status between PG and H28 regarding HPV40, -42, and -54 are in line with PGMY degeneracy. At the extreme, the lack of sensitivity of PGMY-based assays toward HPV68a is due to three mismatches within the PGMY09-L primer, as determined by DNA sequencing of a rare HPV68a PG-positive case from our biobank. This observation allowed designing the HPV68a-specific RSMY09-L primer used in PGv2. PGv2 is currently under prospective validation to ensure that RSMY09-L does not negatively affect the detection of other genotypes. At the time of manuscript submission, PGv2 was not inferior to PG for HPV genotyping ($n = 315$ samples, of which 7 contained HPV68a). PGv2 was, in addition, fully proficient with the 2013 WHO quality control panel, including HPV68a (not shown). The limitation of PGMY-based HPV genotyping assays regarding HPV68a should be taken into account for data evaluation comparing the pre- and postvaccination eras, especially when addressing type replacement possibly involving HPV68.

H28 thus appears very efficient for epidemiological studies using fresh cervical smears. Like PG, it is, however, too sensitive for clinical purposes, if not used as an adjunct to a clinically validated assay. The locations of the H28 primers/probes within the HPV genomes are Seegene's proprietary information. It therefore is impossible to predict whether this assay would be suitable for epidemiological studies using fixed and paraffin-embedded high-grade tumor material, since sensitivity may be affected by the size and genomic location of the amplicons (26). Validation of H28 with such samples therefore would be of interest. Clinical evaluation of H28 with CIN2 and more (CIN2+) or CIN3+ endpoints would also be of interest, because the semiquantitative readout that its technology allows may be suitable for primary cervical cancer screening using clinically relevant HPV genotype-specific detection thresholds (27). If feasible, H28 would address not only HPV type-specific persistence but also clinically relevant infections.

In conclusion, H28 is a very sensitive and specific HPV screening and genotyping assay which may simplify and standardize HPV genotyping. It requires less manpower and expertise than PG or other assays based on reverse hybridization and could be used for large-scale testing thanks to its automation capacity and objective reading.

ACKNOWLEDGMENTS

We gratefully acknowledge the expert technical help of the staff of the molecular diagnostic laboratory at our institute.

The H28 kits and the Bio-Rad CFX96 real-time PCR instrument were provided by Bühlmann Laboratories for the duration of the study. All other costs were covered by R.S.'s own funding.

P. Shaw critically reviewed the manuscript.

We have no conflicts of interests related to BÜHLMANN Laboratories or to Seegene.

ADDENDUM IN PROOF

Seegene now offers a research-use-only (RUO) kit for detection of the HPV51 subtypes that were missed by H28.

REFERENCES

- Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. 2006. Chapter 1: HPV in the etiology of human cancer. *Vaccine* 24S: S31–S10. <http://dx.doi.org/10.1016/j.vaccine.2006.05.115>.
- zur Hausen H. 2009. Papillomaviruses in the causation of human cancers—a brief historical account. *Virology* 384:260–265. <http://dx.doi.org/10.1016/j.virol.2008.11.046>.
- Berkhof J, Bulkman NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ. 2006. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. *Cancer Epidemiol. Biomarkers Prev.* 15:1268–1273. <http://dx.doi.org/10.1158/1055-9965.EPI-05-0764>.
- Boone JD, Erickson BK, Huh WK. 2012. New insights into cervical cancer screening. *J. Gynecol. Oncol.* 23:282–287. <http://dx.doi.org/10.3802/jgo.2012.23.4.282>.
- Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J. 2007. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. *Br. J. Cancer* 97:129–132. <http://dx.doi.org/10.1038/sj.bjc.6603843>.
- Carozzi FM, Burroni E, Bisanzio S, Puliti D, Confortini M, Giorgi Rossi P, Sani C, Scalisi A, Chini F. 2011. Comparison of clinical performance of Abbott RealTime high risk HPV test with that of hybrid capture 2 assay in a screening setting. *J. Clin. Microbiol.* 49:1446–1451. <http://dx.doi.org/10.1128/JCM.02311-10>.
- Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter WP, Lyons D, Szarewski A. 2010. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. *J. Med. Virol.* 82:1186–1191. <http://dx.doi.org/10.1002/jmv.21801>.
- Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, Verkuijden M, Meijer CJ, Snijders PJ. 2011. Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. *J. Clin. Microbiol.* 49:3983–3985. <http://dx.doi.org/10.1128/JCM.05552-11>.
- Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *Int. J. Cancer* 124:516–520. <http://dx.doi.org/10.1002/ijc.24010>.
- Unger ER, Dillner J, Zhou T (ed). 2009. Human papillomavirus laboratory manual, 1st ed. WHO, Geneva, Switzerland.
- Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. *JAMA* 286:3106–3114. <http://dx.doi.org/10.1001/jama.286.24.3106>.
- Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vezina S, Cote P, Macleod J, Voyer H, Forest P, Walmsley S, Franco E. 2006. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. *J. Clin. Microbiol.* 44:1998–2006. <http://dx.doi.org/10.1128/JCM.00104-06>.
- Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. *J. Clin. Microbiol.* 38:357–361.
- Jiang HL, Zhu HH, Zhou LF, Chen F, Chen Z. 2006. Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system. *J. Med. Microbiol.* 55:715–720. <http://dx.doi.org/10.1099/jmm.0.46493-0>.
- Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. *J. Clin. Microbiol.* 37:2508–2517.
- Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. 2006. Bead-based multiplex genotyping of human papillomaviruses. *J. Clin. Microbiol.* 44:504–512. <http://dx.doi.org/10.1128/JCM.44.2.504-512.2006>.
- Soderlund-Strand A, Carlson J, Dillner J. 2009. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. *J. Clin. Microbiol.* 47:541–546. <http://dx.doi.org/10.1128/JCM.02007-08>.
- van Den Brule AJ, Pol R, Franssen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5+ /6+ PCR followed by reverse line blot anal-

- ysis enables rapid and high-throughput identification of human papillomavirus genotypes. *J. Clin. Microbiol.* 40:779–787. <http://dx.doi.org/10.1128/JCM.40.3.779-787.2002>.
19. Wallace J, Woda BA, Pihan G. 2005. Facile, comprehensive, high-throughput genotyping of hum. Genital papillomaviruses using spectrally addressable liquid bead microarrays. *J. Mol. Diagn.* 7:72–80. [http://dx.doi.org/10.1016/S1525-1578\(10\)60011-6](http://dx.doi.org/10.1016/S1525-1578(10)60011-6).
 20. Estrade C, Menoud PA, Nardelli-Haeffliger D, Sahli R. 2011. Validation of a low-cost human papillomavirus genotyping assay based on PGM1 PCR and reverse blotting hybridization with reusable membranes. *J. Clin. Microbiol.* 49:3474–3481. <http://dx.doi.org/10.1128/JCM.05039-11>.
 21. Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE. 2012. High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. *Clin. Chem. Lab. Med.* 50:655–661. <http://dx.doi.org/10.1515/cclm.2011.835>.
 22. Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J, WHO Human Papillomavirus Laboratory Network. 2012. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. *J. Clin. Microbiol.* 50:2289–2298. <http://dx.doi.org/10.1128/JCM.00840-12>.
 23. Eklund C, Zhou T, Dillner J, WHO Human Papillomavirus Laboratory Network. 2010. Global proficiency study of human papillomavirus genotyping. *J. Clin. Microbiol.* 48:4147–4155. <http://dx.doi.org/10.1128/JCM.00918-10>.
 24. Chun JY, Kim KJ, Hwang IT, Kim YJ, Lee DH, Lee IK, Kim JK. 2007. Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene. *Nucleic Acids Res.* 35:e40. <http://dx.doi.org/10.1093/nar/gkm051>.
 25. Cho CH, Chulten B, Lee CK, Nam MH, Yoon SY, Lim CS, Cho Y, Kim YK. 2013. Evaluation of a novel real-time RT-PCR using TOCE technology compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses. *J. Clin. Virol.* 57:338–342. <http://dx.doi.org/10.1016/j.jcv.2013.04.014>.
 26. Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B, Hagmar B. 1996. Use of multiple PCR primer sets for optimal detection of human papillomavirus. *J. Clin. Microbiol.* 34:2095–2100.
 27. Snijders PJ, van den Brule AJ, Meijer CJ. 2003. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. *J. Pathol.* 201:1–6. <http://dx.doi.org/10.1002/path.1433>.